Literature DB >> 33481910

Single nucleotide polymorphism leads to daptomycin resistance causing amino acid substitution-T345I in MprF of clinically isolated MRSA strains.

Masaki Nakamura1,2,3, Hayato Kawada2, Hiroki Uchida1, Yusuke Takagi1, Shuichi Obata4,5, Ryotaro Eda2, Hideaki Hanaki3, Hidero Kitasato1,2.   

Abstract

Daptomycin (DAP) is one of the most potent antibiotics used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Due to an increase in its administration for combating MRSA infections, DAP non-susceptible (DAP-NS) MRSA strains have recently been reported in clinical settings. The presence of single nucleotide polymorphisms (SNPs) in the multiple peptide resistance factor (mprF) gene is the most frequently reported cause for the evolution of DAP-NS MRSA strains; however, there are some variations of SNPs that could lead to DAP-NS. In this study, we used two clinical MRSA strains, including DAP susceptible (DAP-S) and DAP-NS, isolated from the same patient at different time points. We introduced T345I SNP to mprF of the DAP-S MRSA strain using the gene exchange method with pIMAY vector. Further, we investigated the phenotype of the mutant strain, including drug susceptibility, cell surface positive charge, and growth speed. The mutant strain exhibited (i) resistance to DAP, (ii) up-regulation of positive surface charge, (iii) slower growth speed, and (iv) thickened cell walls. Hence, the SNP in mprF may have caused an up-regulation in MprF function, with a subsequent increase in positive surface charge. Cumulatively, these results demonstrated that the T345I amino acid substitution in mprF represents one of the primary causes of DAP-NS in MRSA strains.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33481910      PMCID: PMC7822245          DOI: 10.1371/journal.pone.0245732

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  29 in total

1.  Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.

Authors:  C W Stratton; C Liu; H B Ratner; L S Weeks
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Authors:  Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois Ednie; Laura Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 3.  Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids.

Authors:  Christoph M Ernst; Andreas Peschel
Journal:  Mol Microbiol       Date:  2011-03-01       Impact factor: 3.501

4.  Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient--importance of low-level resistance to vancomycin.

Authors:  Isao Haraga; Shuichi Nomura; Shigeru Fukamachi; Hiroyuki Ohjimi; Hideaki Hanaki; Keiichi Hiramatsu; Ariaki Nagayama
Journal:  Int J Infect Dis       Date:  2002-12       Impact factor: 3.623

5.  Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  Ryan Yu; Suzanne E Dale; Deborah Yamamura; Vida Stankus; Christine Lee
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

6.  Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.

Authors:  Yu-Tsung Huang; Cheng-Hsiang Hsiao; Chun-Hsing Liao; Chung-Wei Lee; Po-Ren Hsueh
Journal:  J Clin Microbiol       Date:  2008-01-16       Impact factor: 5.948

7.  Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides.

Authors:  Arnold S Bayer; Nagendra N Mishra; George Sakoulas; Poochit Nonejuie; Cynthia C Nast; Joseph Pogliano; Kuan-Tsen Chen; Steven N Ellison; Michael R Yeaman; Soo-Jin Yang
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

8.  Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus.

Authors:  Anton Y Peleg; Spiros Miyakis; Doyle V Ward; Ashlee M Earl; Aileen Rubio; David R Cameron; Satish Pillai; Robert C Moellering; George M Eliopoulos
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

9.  Fitness Cost of Daptomycin-Resistant Staphylococcus aureus Obtained from in Vitro Daptomycin Selection Pressure.

Authors:  Shuguang Li; Yuyao Yin; Hongbin Chen; Qi Wang; Xiaojuan Wang; Hui Wang
Journal:  Front Microbiol       Date:  2017-11-09       Impact factor: 5.640

10.  Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Matthew Geriak; Fadi Haddad; Khulood Rizvi; Warren Rose; Ravina Kullar; Kerry LaPlante; Marie Yu; Logan Vasina; Krista Ouellette; Marcus Zervos; Victor Nizet; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

View more
  2 in total

1.  Catalase Protects Biofilm of Staphylococcus aureus against Daptomycin Activity.

Authors:  Cristina El Haj; Mads Lichtenberg; Karen Leth Nielsen; Thomas Bjarnsholt; Peter Østrup Jensen
Journal:  Antibiotics (Basel)       Date:  2021-04-30

Review 2.  Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort.

Authors:  Elizabeth V K Ledger; Akshay Sabnis; Andrew M Edwards
Journal:  Microbiology (Reading)       Date:  2022-02       Impact factor: 2.777

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.